{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:24Z","timestamp":1791245184124,"version":"4.1.0"},"reference-count":128,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>BTK (Bruton\u2019s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL\/SLL. As a central mediator of B-cell receptor signaling and microenvironment interactions, BTK supports survival, proliferation, and trafficking in multiple mature B-cell malignancies (mantle cell lymphoma, marginal zone lymphoma, Waldenstr\u00f6m macroglobulinemia, and other indolent\/aggressive lymphomas) and in selected immune-mediated conditions such as chronic graft-versus-host disease. Covalent BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib) irreversibly bind the C481 residue and have produced high response rates and durable disease control, often replacing chemoimmunotherapy in the relapsed setting and, for some entities, even in the first line. Differences in kinase selectivity lead to different safety profiles: second-generation covalent agents generally maintain efficacy while reducing significant off-target toxicities, especially atrial fibrillation and hypertension. Resistance to covalent BTK inhibitors most commonly develops through BTK C481 substitutions and activating PLCG2 mutations, with other kinase-domain variants increasingly recognized. Non-covalent BTK inhibitors (e.g., pirtobrutinib) bind BTK independently of C481, can overcome classic C481-mediated resistance, and extend BTK pathway targeting into later lines of therapy. Overall, BTK inhibition has evolved into a versatile platform enabling long-term, often chemo-free management strategies.<\/jats:p>","DOI":"10.3390\/biom16010123","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:30:34Z","timestamp":1768203034000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BTK Inhibition in Hematology: From CLL\/SLL to Emerging Applications Across B-Cell and Immune Disorders"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4079-7899","authenticated-orcid":false,"given":"Paola","family":"De Luca","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anastasia","family":"Caruso","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Lavenia","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scarso","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-805X","authenticated-orcid":false,"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4896-6666","authenticated-orcid":false,"given":"Fanny Erika","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell\u2019Alto Adige), Teaching Hospital of Paracelsus Medical University, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Hematology with BMT Unit, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d, 95123 Catania, Italy"},{"name":"Department of Medical Surgical Sciences and Advanced Technologies \u201cG.F. Ingrassia\u201d, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) Function Is Important to the Development and Expansion of Chronic Lymphocytic Leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK Inhibitors in CLL: Second-Generation Drugs and Beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors: Present and Future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 3.2022: Featured Updates to the NCCN Guidelines","volume":"20","author":"Wierda","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline Interim Update on New Targeted Therapies in the First Line and at Relapse of Chronic Lymphocytic Leukaemia 5 on Behalf of the ESMO Guidelines Committee","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1097\/HS9.0000000000000520","article-title":"EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia","volume":"5","author":"Eichhorst","year":"2020","journal-title":"Hemasphere"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1007\/s00277-025-06686-3","article-title":"Diffuse Large B-Cell Lymphoma in the New Era: Prognostic Tools for Mapping Risk","volume":"104","author":"Duminuco","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"IwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2010.01.004","article-title":"Autoimmune Complications in Chronic Lymphocytic Leukemia (CLL)","volume":"23","author":"Zent","year":"2010","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.genhosppsych.2007.01.014","article-title":"Depression, Anxiety and Quality of Life in a Chronic Lymphocytic Leukemia Cohort","volume":"29","author":"Levin","year":"2007","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ajh.26585","article-title":"Unusual Complications in the Management of Chronic Lymphocytic Leukemia","volume":"97","author":"Gordon","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dearden, C. (2008). Disease-Specific Complications of Chronic Lymphocytic Leukemia. Hematol. Am. Soc. Hematol. Educ. Program, 450\u2013456.","DOI":"10.1182\/asheducation-2008.1.450"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Romano, A., Leotta, D., La Spina, E., Cambria, D., Bulla, A., Del Fabro, V., Tibullo, D., Giallongo, C., and Palumbo, G.A. (2023). Clinical Outcome of SARS-CoV-2 Infections Occurring in Multiple Myeloma Patients after Vaccination and Prophylaxis with Tixagevimab\/Cilgavimab. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1157610"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cncr.35005","article-title":"Efficacy and Safety of Tixagevimab-Cilgavimab versus SARS-CoV-2 Breakthrough Infection in the Hematological Conditions","volume":"130","author":"Duminuco","year":"2024","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and Future Treatment Strategies in Chronic Lymphocytic Leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-981-15-3532-1_2","article-title":"B Cell Receptor Signaling","volume":"1254","author":"Tanaka","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tkachenko, A., Kupcova, K., and Havranek, O. (2023). B-Cell Receptor Signaling and Beyond: The Role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in Normal and Malignant B Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010010"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(00)80153-3","article-title":"BLNK: Connecting Syk and Btk to Calcium Signals","volume":"12","author":"Kurosaki","year":"2000","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Smith, C.I.E., and Burger, J.A. (2021). Resistance Mutations to BTK Inhibitors Originate From the NF-\u039aB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.689472"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Estupi\u00f1\u00e1n, H.Y., Bergl\u00f6f, A., Zain, R., and Smith, C.I.E. (2021). Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK Inhibition Results in Impaired CXCR4 Chemokine Receptor Surface Expression, Signaling and Function in Chronic Lymphocytic Leukemia","volume":"30","author":"Chen","year":"2015","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000533610","article-title":"Chronic Lymphocytic Leukemia: Disease Biology","volume":"147","author":"Koehrer","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and Pharmacodynamic Evaluation of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia: Rationale for Lower Doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Palma, M., Mulder, T.A., and \u00d6sterborg, A. (2021). BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.686768"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/EDBK_320117","article-title":"Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas","volume":"41","author":"Shah","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Montoya, S., and Thompson, M.C. (2023). Non-Covalent Bruton\u2019s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15143648"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal Evolution Leading to Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 Remain Unmutated in One-Third of Patients with CLL Relapsing on Ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK Gatekeeper Residue Variation Combined with Cysteine 481 Substitution Causes Super-Resistance to Irreversible Inhibitors Acalabrutinib, Ibrutinib and Zanubrutinib","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.20517\/cdr.2023.97","article-title":"Targeting BCL2 Pathways in CLL: A Story of Resistance and Ingenuity","volume":"6","author":"Reyes","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-up of First-Line Ibrutinib Treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-Year Follow-up from RESONATE-2: First-Line Ibrutinib Treatment for Patients with Chronic Lymphocytic Leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 Study Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-Term Outcomes for Ibrutinib\u2013Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without Obinutuzumab versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in Treatment-Naive CLL in the 6-Year Follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (SEQUOIA): A Randomised, Controlled, Phase 3 Trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib Versus Bendamustine and Rituximab in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib Monotherapy for Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia and 17p Deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-Duration Ibrutinib plus Venetoclax for First-Line Treatment of CLL: Primary Analysis of the CAPTIVATE FD Cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/JCO.2025.43.16_suppl.7036","article-title":"Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study","volume":"43","author":"Ghia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","first-page":"24","article-title":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia","volume":"393","author":"Stumpf","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Na\u00efve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease","volume":"43","author":"Davids","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and Rituximab versus Fludarabine, Cyclophosphamide, and Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (FLAIR): Interim Analysis of a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational Profile in Previously Treated Patients with Chronic Lymphocytic Leukemia Progression on Acalabrutinib or Ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"Ascend: Phase III, Randomized Trial of Acalabrutinib versus Idelalisib plus Rituximab or Bendamustine plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final Analysis from RESONATE: Up to Six Years of Follow-up on Ibrutinib in Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients with R\/R CLL\/SLL: Final Comparative Analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 6-Year Results of the Randomized Phase 3 CLL14 Study","volume":"144","author":"Robrecht","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus Obinutuzumab versus Chlorambucil plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-up Results from a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study","volume":"39","author":"Zhang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/bloodadvances.2023011569","article-title":"Hypertension Treatment for Patients Receiving Ibrutinib: A Multicenter Retrospective Study","volume":"8","author":"Samples","year":"2024","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","volume":"18","author":"Hillmen","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO Study: Final Analysis and Retreatment\/Crossover Substudy Results of VenR for Patients with Relapsed\/Refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Nayyar, M., de Menezes, R.C.B., Ailawadhi, S., and Parrondo, R.D. (2025). Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation. Cancers, 17.","DOI":"10.3390\/cancers17142298"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene Maraleucel in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (TRANSCEND CLL 004): A Multicentre, Open-Label, Single-Arm, Phase 1\u20132 Study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","article-title":"Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Primary results from the open-label, phase 1\/2 transcend CLL 004 study","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"key":"ref_73","unstructured":"Wierda, W. (2025, December 15). CHARACTERISTICS ASSOCIATED WITH RESPONSE TO LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH R\/R CLL\/SLL: EXPLORATORY ANALYSES FROM TRANSCEND CLL 004. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422262\/william.g.wierda.characteristics.associated.with.response.to.lisocabtagene.html."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-Cell Receptor Signaling as a Driver of Lymphoma Development and Evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-Term Follow-up of MCL Patients Treated with Single-Agent Ibrutinib: Updated Safety and Efficacy Results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus Temsirolimus in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: An International, Randomised, Open-Label, Phase 3 Study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e777","DOI":"10.1016\/S2352-3026(25)00252-2","article-title":"Rituximab, Bendamustine, and Cytarabine Followed by Venetoclax in Older Patients with High-Risk Mantle Cell Lymphoma (FIL_V-RBAC): A Multicentre, Single-Arm, Phase 2 Study","volume":"12","author":"Visco","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_80","first-page":"343","article-title":"Final Results and Overall Survival Data from a Phase II Study of Acalabrutinib Monotherapy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma, Including Those with Poor Prognostic Factors","volume":"109","author":"Rule","year":"2023","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","article-title":"Zanubrutinib Monotherapy in Relapsed\/Refractory Mantle Cell Lymphoma: A Pooled Analysis of Two Clinical Trials","volume":"14","author":"Zhou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in Relapsed\/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s00277-024-05752-6","article-title":"Monocyte-to-Platelets Ratio (MPR) at Diagnosis Is Associated with Inferior Progression-Free Survival in Patients with Mantle Cell Lymphoma: A Multi-Center Real-Life Survey","volume":"103","author":"Duminuco","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_86","first-page":"715","article-title":"Safety and Efficacy of Acalabrutinib plus Bendamustine and Rituximab in Patients with Treatment-Na\u00efve or Relapsed\/Refractory Mantle Cell Lymphoma: Phase Ib Trial","volume":"110","author":"Phillips","year":"2025","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable Ibrutinib Responses in Relapsed\/Refractory Marginal Zone Lymphoma: Long-Term Follow-up and Biomarker Analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and Efficacy of Zanubrutinib in Relapsed\/Refractory Marginal Zone Lymphoma: Final Analysis of the MAGNOLIA Study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr\u00f6m\u2019s Macroglobulinemia: Final Analysis From the Randomized Phase III INNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: Final Analysis from the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non\u2013Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.2025028649","article-title":"A Phase 2 Study of Zanubrutinib in Combination with Rituximab and Lenalidomide in de Novo Diffuse Large B-Cell Lymphoma","volume":"146","author":"Xu","year":"2025","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-022-00314-w","article-title":"Rituximab, Lenalidomide and BTK Inhibitor as Frontline Treatment for Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Single Center","volume":"11","author":"Zhu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Geng, H., Jia, S., Zhang, Y., Li, J., Yang, Q., Zeng, L., Zong, X., Lu, Y., Lu, S., and Zhou, J. (2023). Efficacy and Safety of Zanubrutinib plus R-CHOP in Treatment of Non-GCB DLBCL with Extranodal Involvement. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1219167"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/neurolint14010009","article-title":"Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review","volume":"14","author":"Nepal","year":"2022","journal-title":"Neurol. Int."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Zhu, S., Gokhale, S., Jung, J., Spirollari, E., Tsai, J., Arceo, J., Wu, B.W., Victor, E., and Xie, P. (2021). Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets\u2014Beyond B Lymphocytes. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.727531"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton Tyrosine Kinase Inhibitors for Multiple Sclerosis","volume":"19","author":"Turner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Burchett, J.R., Dailey, J.M., Kee, S.A., Pryor, D.T., Kotha, A., Kankaria, R.A., Straus, D.B., Ryan, J.J., Kalyuzhny, E., and Francis, H. (2022). Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells, 11.","DOI":"10.3390\/cells11193031"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1158\/0008-5472.CAN-18-3139","article-title":"ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT","volume":"79","author":"Winger","year":"2019","journal-title":"Cancer Res."},{"key":"ref_105","first-page":"355","article-title":"Antineoplastic Efficacy Profiles of Avapritinib and Nintedanib in KIT D816V+ Systemic Mastocytosis: A Preclinical Study","volume":"13","author":"Gamperl","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Maugeri, C., Parisi, M., Mauro, E., Fiumara, P.F., Randazzo, V., Salemi, D., Agueli, C., Palumbo, G.A., and Santoro, A. (2022). Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers, 14.","DOI":"10.3390\/cancers14092186"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Vecchio, V., Duminuco, A., Leotta, S., Mauro, E., Maugeri, C., Parisi, M., Fiumara, P.F., Di Raimondo, F., Palumbo, G.A., and Gozzo, L. (2025). Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort. J. Clin. Med., 14.","DOI":"10.3390\/jcm14145110"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","article-title":"Ibrutinib for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease: A Multicenter Real-World Analysis","volume":"9","author":"Pidala","year":"2025","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study","volume":"41","author":"Miklos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/14656566.2023.2228695","article-title":"The Pharmacotherapeutic Management of Patients with Myelofibrosis: Looking beyond JAK Inhibitors","volume":"24","author":"Duminuco","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11899-023-00702-x","article-title":"A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases","volume":"1","author":"Duminuco","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kuykendall, A., Duminuco, A., Chifotides, H.T., Giallongo, S., Giallongo, C., Tibullo, D., and Palumbo, G.A. (2023). ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. Cancers, 16.","DOI":"10.3390\/cancers16010154"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11899-025-00751-4","article-title":"Emerging Therapeutic Approaches for Anemia in Myelofibrosis","volume":"20","author":"Chifotides","year":"2025","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Gozzo, L., Leotta, S., Romano, G.L., Vetro, C., Duminuco, A., Milone, G., Cupri, A., Palumbo, F.E., Brancati, S., and Ruscica, R. (2024). Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144273"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and Efficacy of Rilzabrutinib vs Placebo in Adults with Immune Thrombocytopenia: The Phase 3 LUNA3 Study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/s41375-025-02681-9","article-title":"QRISK3 Score Is Predictive of Thrombotic Risk in Patients with Myeloproliferative Neoplasms","volume":"39","author":"Duminuco","year":"2025","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1002\/hem3.143","article-title":"Development of a Natural Language Processing Pipeline for Assessment of Cardiovascular Risk in Myeloproliferative Neoplasms","volume":"8","author":"Duminuco","year":"2024","journal-title":"Hemasphere"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Galitzia, A., Maccaferri, M., Mauro, F.R., Murru, R., and Marasca, R. (2024). Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents. Cancers, 16.","DOI":"10.3390\/cancers16111996"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104408","DOI":"10.1016\/j.critrevonc.2024.104408","article-title":"Severe Infections in Patients with Chronic Lymphocytic Leukemia Included in Trials Investigating BTK and BCL2 Inhibitors","volume":"201","author":"Mauro","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00277-024-05625-y","article-title":"Prediction of Severe Infections in Chronic Lymphocytic Leukemia: A Simple Risk Score to Stratify Patients at Diagnosis","volume":"103","author":"Murru","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing Toxicities of Bruton Tyrosine Kinase Inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"12145","DOI":"10.1200\/JCO.2024.42.16_suppl.12145","article-title":"Risk Assessment of Cardiovascular Adverse Events with BTK Inhibitors in Hematological Malignancies: Insights from FAERS","volume":"42","author":"Faisal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101268","DOI":"10.1016\/j.blre.2025.101268","article-title":"BTKi-Induced Cardiovascular Toxicity in CLL: Risk Mitigation and Management Strategies","volume":"70","author":"Kozarac","year":"2025","journal-title":"Blood Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-020-04137-6","article-title":"Drug Interactions with Bruton\u2019s Tyrosine Kinase Inhibitors: Clinical Implications and Management","volume":"86","author":"Fancher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Del Fabro, V., De Luca, P., Leotta, D., Limoli, M.C., Longo, E., Nardo, A., Santuccio, G., Petronaci, A., and Stanzione, G. (2024). Emergencies in Hematology: Why, When and How I Treat?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247572"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: A Randomized, Double-Blind, Phase III Pivotal Study of Febuxostat versus Allopurinol for the Prevention of Tumor Lysis Syndrome (TLS) in Patients with Hematologic Malignancies at Intermediate to High TLS Risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:48:30Z","timestamp":1768204110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["biom16010123"],"URL":"https:\/\/doi.org\/10.3390\/biom16010123","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}